Changes in Pathological Complete Response Rates after Neoadjuvant Chemotherapy for Breast Carcinoma over Five Years
Table 1
Cohort demographics and clinical characteristics.
Characteristic
Entire cohort
Time period 1:
Time period 2:
Test statistic
Mean (SD)
Mean (SD)
Mean (SD)
()
Age
51.1 (13.1)
53.19 (11.30)
48.85 (14.70)
1.72 (0.09)
Initial tumor size (cm)
3.35 (2.2)
3.43 (2.2)
2.49 (1.48)
2.51 (0.01)
BMI
27.8 (7.4)
28.81 (8.13)
26.7 (6.43)
1.50 (0.14)
(%)
(%)
(%)
()
Clinical LAD
65 (57.5)
37 (61.7)
28 (52.8)
0.88 (0.35)
Hormonal receptor positive only
33 (29.2)
22 (36.7)
11 (20.7)
4.18 (0.04)
HER2+
43 (38.1)
17 (28.3)
26 (49.1)
4.92 (0.03)
TNBC
37 (32.7)
21 (35.0)
16 (30.2)
0.28 (0.60)
pCR overall
30 (26.5)
8 (13.3)
22 (41.5)
11.36 (0.001)
BMI: body mass index; HER2: human epidermal growth factor receptor 2; LAD: lymphadenopathy; NACT: neoadjuvant chemotherapy; pCR: pathological complete response; time period 1: before 12/2013; time period 2: after 12/2013; TNBC: triple negative breast cancer. Notes. and .
